<DOC>
	<DOCNO>NCT01927497</DOCNO>
	<brief_summary>Rationale : Approximately 800 abdominoperineal resection ( APR ) perform rectal cancer year Netherlands . The extralevator approach ( eAPR ) reduce rate positive margin improve oncological outcome distal rectal cancer . However , wide excision increase wound heal problem development perineal hernia . This result progressive increase use musculocutaneous flap biological mesh associate substantial increase cost , support proper data . Objective : The aim study determine cost-effectiveness pelvic floor reconstruction use biological mesh standardize eAPR neo-adjuvant ( chemo ) radiotherapy . Study design : This multicenter study patient undergo eAPR randomize standard care use primary closure perineum experimental arm assist closure use biological mesh . Study population : Patients clinical diagnosis primary rectal cancer schedule eAPR neo-adjuvant ( chemo ) radiotherapy . A total number 104 patient randomize . Intervention : The intervention experimental arm consist suture biological mesh derive porcine dermis pelvic floor defect , follow perineal closure similar control arm . Main study parameters/endpoints : The primary endpoint percentage uncomplicated perineal wound heal ( Souphampton wound score less II day 30 ) . Secondary endpoint hospital stay , incidence perineal hernia , quality life , cost . Nature extent burden risk associate participation , benefit group relatedness : Both primary perineal closure biological mesh assist closure perform daily clinical practise . The potential benefit result participation study patient randomize biological mesh assist closure may higher chance uncomplicated perineal wound heal low perineal hernia rate . On hand , use biological mesh associate increase postoperative pain seroma formation .</brief_summary>
	<brief_title>Biological Mesh Closure Pelvic Floor After Extralevator Abdomino Perineal Resection Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>1 . Age 18 year higher . 2 . Planned eAPR primary rectal cancer . 3 . Life expectancy 2 year . 4 . Ability return schedule require study visit . 5 . Preoperative ( chemo ) radiotherapy . 6 . Written inform consent study participation . 1 . Previous pelvic irradiation cancer ( i.e . prostate cancer ) . 2 . Total exenteration sacral resection level S4/S5 . 3 . Sensitivity porcine derive product polysorbate . 4 . Severe systemic disease affect wound healing ( i.e . renal failure require dialysis , liver cirrhosis , immune compromise status like HIV ) . 5 . Collagen disorder ( i.e . Marfan ) . 6 . Enrolment trial overlap primary endpoint otherwise expect influence wound healing ( i.e . biological therapy like antiangiogenic agent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rectal cancer</keyword>
	<keyword>Extralevator abdominoperineal resection</keyword>
	<keyword>Biological Mesh</keyword>
	<keyword>Primary closure</keyword>
</DOC>